

Onyx Dkt No. 1046.ORD USSN: 09/410,462

PATENT

CERTIFICATE OF FIRST CLASS MAILING (37 CFR 1.8)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail, with sufficient postage, in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the following date:

13 Nov 200 6
Date

Jan N. Fabran Signature

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Williams, A., et al. Confirmation No. 6889

Serial No.: 09/410,462 Art Unit: 1635

Filing Date: 1 October 1999 Examiner: J.E. Angell

Title: A SINGLE AGENT METHOD FOR KILLING TUMOR AND TUMOR ASSOCIATED

ENDOTHELIAL CELLS USING ADENOVIRAL MUTANTS

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing are an Information Disclosure Statement, a modified Form PTO-1449, listing seven U.S. Patents and two non-U.S. Patent publications, and copies of the two non-U.S. Patent publications.

Copies of the cited U.S. Patents are not enclosed pursuant the "Changes to Support Implementation of the United States Patent and Trademark Office 21st Century Strategic Plan," Federal Register, Vol. 69, No. 182.

The Examiner is respectfully requested to make this information of official record in the application.

This Information Disclosure Statement under 37 CFR § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the

11/16/2006 SDENBOB1 00000018 150615 09410462 02 FC:1806 180.00 DA

Onyx Dkt No. 1046.ORD USSN: 09/410,462

PATENT

like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

The Commissioner is hereby authorized to the fee (37 C.F.R. §1.17(p)) for this Information Disclosure Statement (\$180.00) to Deposit Account No. 15-0615 (please reference ONYX1046.ORD). No further fees are believed due. However, the Commissioner is authorized to charge any fees under 37 C.F.R. §§ 1.16, 1.17 and 1.21 which may be required by this paper, or to credit any overpayment, to Deposit Account No. 15-0615. This is not authorization to pay the Issue Fee.

Respectfully submitted,

Dated: 3 Nov Zou6

By

Gary R. Fabian
Agent for Applicants


Registration No. 33,875

ONYX Pharmaceuticals, Inc.

2100 Powell Street

Emeryville, CA 94608 Phone: (510) 597-6502

Facsimile: (510) 597-6610



Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450



FORM PTO-1449 (Modified)
LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT
(Use several sheets if necessary)
Sheet 1 of 2

In the Application of: Williams, A., et al.

Serial No.: 09/410,462

9/410,462 Art Unit: 1635

Filed: 1 October 1999 Examiner: J.E. Angell

Title: A SINGLE AGENT METHOD FOR KILLING TUMOR AND TUMOR ASSOCIATED ENDOTHELIAL CELLS

Confirmation No.: 6889

USING ADENOVIRAL MUTANTS

U.S. PATENT DOCUMENTS							
Exam. Init.	Ref. Desig.	Document No.	Date	Name	Class	Sub Class	Filing Date
	AD-01	5,677,178	October 14, 1997	McCormick			
	AD-02	5,801,029	September 1, 1998	McCormick			
	AD-03	5,846,945	December 8, 1998	McCormick	 		
	AD-04	5,856,181	January 5, 1999	McCormick		 	
•	AD-05	6,296,845	October 2, 2001	Sampson- Johannes, et al.			
	AD-06	7,001,596	February 21, 2006	Johnson, et al.			
	AD-07	7,078,030	July 18, 2006	Johnson, et al.	1	+	

FOREIGN PATENT DOCUMENTS								
Exam. Init.	Ref. Desig.	Document No.	Publication Date	Country or Patent Office	Class	Sub Class	Transla YES	ation NO
_	BD-01							

Examiner:	Date Considered:

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

ONYX Dkt No.: ONYX1046.ORD

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

FORM PTO-1449 (Modified) LIST OF PATENTS AND PUBLICATIONS FOR APPLICANT'S INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary) Sheet 2 of 2

In the Application of: Williams, A., et al.

Serial No.: 09/410,462

Confirmation No.: 6889

Art Unit: 1635

Filed: 1 October 1999 Examiner: J.E. Angell

Title: A SINGLE AGENT METHOD FOR KILLING TUMOR AND TUMOR ASSOCIATED ENDOTHELIAL CELLS

USING ADENOVIRAL MUTANTS

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)				
Exam. Init.	Ref. Desig.	Description		
-1. 400	CD-01	Berse, B., et al., "Vascular Permeability Factor (Vascular Endothelial Growth Factor) Gene is Expressed Differentially in Normal Tissues, Macrophages, and Tumors," Molec. Biol. Cell 1992 Feb;3(2):211-20)		
	CD-02	Warren, R.S., et al., "Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis," J. Clin. Invest. 1995 Apr;95(4):1789-97		

-	D 4 O 11 1
Examiner:	Date Considered:
2X41111101.	

EXAMINER: Initial if citation considered whether or not the citation conforms with MPEP609. Draw a line through the citation if not in conformance and not considered. Include copy of this form with next communication to applicant.